You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 83 No. 3, March 1970 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (14)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Intraocular Pressure and Outflow Facility

Effect of Estrogen and Combined Estrogen-Progestin Treatment in Normal Human Eyes

Giora Treister, MD; Shlomo Mannor, MD

Arch Ophthalmol. 1970;83(3):311-318.


Abstract

Continuous treatment with mestranol, 0.1 mg/ day, in normal women, caused a small gradually growing intraocular pressure decrease of 2.0 ± 0.45 mm Hg and an outflow facility increase of 0.085µl ± 0.015µl (min mm Hg)-1 at six months. Treatment of another group of 15 normal women with mestranol + ethynodiol diacetate in doses of 0.1 mg and 1.0 mg per day, respectively, gave similar results. The decrease in intraocular pressure was 1.8 ± 0.38 mm Hg at six months, and the increase in outflow facility was 0.056µl ± 0.01µl (min mm Hg)-1 at six months. In both groups, the effect of the drugs on intraocular pressure and outflow facility was highly significant (P < 0.001). However, the differences between the two groups were not significant. Reasons are presented for the belief that the drugs act on the trabecular meshwork.



Author Affiliations

Tel Aviv, Israel

From the departments of ophthalmology (Dr. Treister) and obstetrics and gynecology (Dr. Mannor), Tel-Hashomer Government Hospital, Tel Aviv University Medical School, Israel. Dr. Treister is now with the Department of Pharmacology, University of Uppsala, Sweden.


Footnotes

Submitted for publication Sept 2, 1969.

Reprint requests to Pharmacological Institute, Box 573, 751 23 Uppsala, Sweden (Dr. Treister).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Female reproductive factors and open angle glaucoma: the Blue Mountains Eye Study
Lee et al.
Br J Ophthalmol 2003;87:1324-1328.
ABSTRACT | FULL TEXT  

Estrogen Protects Lenses against Cataract Induced by Transforming Growth Factor-{beta} (TGF{beta})
Hales et al.
JEM 1997;185:273-280.
ABSTRACT | FULL TEXT  

Daily Assessment of Ocular and Hormonal Variables Throughout the Menstrual Cycle
Feldman et al.
Arch Ophthalmol 1978;96:1835-1838.
ABSTRACT  

Pharmacology and Toxicology: Cellular Response to Drugs Affecting Aqueous Dynamics
Richardson
Arch Ophthalmol 1973;89:65-84.
 





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1970 American Medical Association. All Rights Reserved.